Efficacy and safety of tacrolimus and pimecrolimus ointment on vitiligo: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 9, Issue 7, 2009, Pages 788-795

  Wu, Yan ^a   Liu, Yu Bo ^a   Zhu, Xia ^a   Dong, Guang Hui ^a   Gu, Xiao Chuan ^a   Gao, Xing Hua ^a   Chen, Hong Duo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Pimecrolimus; Randomized controlled trial; Systematic review; Tacrolimus; Vitiligo

Indexed keywords

PIMECROLIMUS; TACROLIMUS;

CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; OINTMENT; REVIEW; SKIN PIGMENTATION; SYSTEMATIC REVIEW; VITILIGO;

EID: 70349318465     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol, 2005, 153(3): 498-505.
2. Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A double-blind, placebo-controlled clinical trial. J Dermatolog Treat, 2008, Jun 16: 1-5. [Epub ahead of print].
3. Kawalek AZ, Spencer JM and Phelps RG. Combined Excimer Laser and Topical Tacrolimus for the Treatment of Vitiligo: A Pilot Study. Dermatol Surg, 2004, 30(2 Pt 1): 130-135.
4. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol, 2004, 140(9): 1065-1069. (Pubitemid 39223113)
5. Mehrabi D and Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol, 2006, 142(7): 927-929. (Pubitemid 44079798)
6. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo. Arch Dermatol, 2003,139(5): 581-585. (Pubitemid 36576373)
7. Dawid M, Veensalu M, Grassberger M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: Results of a randomized, double-blind,vehicle-controlled study. J Dtsch Dermatol Ges, 2006, 4(11): 942-1926 (Pubitemid 44671823)